Showing posts from April, 2024Show all
health-issue
Press Release: Annual General Meeting of April 30, 2024
https://ift.tt/nmI1b3M from Sanofi - Aventis Groupe https://ift.tt/4DFqE9X via IFTTT
Read more
health-issue
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
https://ift.tt/aoqECAH New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediat…
Read more
health-issue
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
https://ift.tt/xm79v8C Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance from Sanofi - Aventis Groupe https://ift…
Read more
health-issue
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
https://ift.tt/RTNLqsW Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia from Sanofi - Aventis Groupe https://ift…
Read more
health-issue
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
https://ift.tt/EC0Dfb2 New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis from Sanofi - Avent…
Read more
